ANDRES MANUEL R
CERVANTES RUIPEREZ
CATEDRÁTICO/A DE UNIVERSIDAD
Beth Israel Deaconess Medical Center
Boston, Estados UnidosPublicacións en colaboración con investigadores/as de Beth Israel Deaconess Medical Center (3)
2023
-
Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer
ESMO Open, Vol. 8, Núm. 2
2019
-
Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors
Clinical Cancer Research, Vol. 25, Núm. 11, pp. 3220-3228
2013
-
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement
Cancer Discovery, Vol. 3, Núm. 4, pp. 406-417